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We sought datasets with granular age distributions of rotavirus-positive disease presentations among children <5 years of age, 
before the introduction of rotavirus vaccines. We identified 117 datasets and fit parametric age distributions to each country 
dataset and mortality stratum. We calculated the median age and the cumulative proportion of rotavirus gastroenteritis events 
expected to occur at ages between birth and 5.0 years. The median age of rotavirus-positive hospital admissions was 38 weeks 
(interquartile range [IQR], 25–58 weeks) in countries with very high child mortality and 65 weeks (IQR, 40–107 weeks) in 
countries with very low or low child mortality. In countries with very high child mortality, 69% of rotavirus-positive admissions 
in children <5 years of age were in the first year of life, with 3% by 10 weeks, 8% by 15 weeks, and 27% by 26 weeks. This infor-
mation is critical for assessing the potential benefits of alternative rotavirus vaccination schedules in different countries and for 
monitoring program impact.
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Rotavirus gastroenteritis (RVGE) is estimated to cause ap-
proximately 200  000 child deaths each year [1]. More than 
half of the countries in the world now include live oral ro-
tavirus vaccines in their national immunization programs 
[2]. There are 4 vaccines licensed for global use (Rotarix, 
GlaxoSmithKline; RotaTeq, Merck & Co; ROTAVAC, Bharat 
Biologicals; and ROTASIIL, Serum Institute of India), others 
for national use (eg, in Vietnam, China), and several others in 
the pipeline, including neonatal and nonreplicating injectable 
vaccines [3]. Rotavirus vaccines are currently coadministered 
with other vaccines that are already part of the routine immu-
nization schedule. Most high-mortality countries use Rotarix, 
administered in 2 doses at 6 and 10 weeks of age. However, 
there is variation in the brand of vaccine used, as well as the 
target number of doses, target ages, and actual coverage and 
timeliness of each dose. The World Health Organization 
(WHO) recommends administering the first dose from 6 
weeks of age, with an interval of at least 4 weeks between 
doses [4]. Randomized controlled trials have reported high 
vaccine efficacy (~90%) against severe RVGE in low-mortal-
ity countries but modest efficacy (~50%) in higher-mortality 
settings [5]. Alternative schedules are being considered to in-
crease their impact. A  neonatal vaccine has had promising 
results in Indonesia [6], and some studies have evaluated the 
potential of a booster dose given at around 9–12 months of 
age [7, 8]. Several studies and surveillance systems have col-
lected information on RVGE age distributions, but much of it 
is unpublished or has been published in age bands that are too 
broad to allow a detailed assessment of the potential impact 
of alternative rotavirus vaccination schedules. More granular 
age distributions would also help to quantify the number of 
RVGE cases expected to occur at specific ages, so that changes 
can be monitored after vaccination. More generally, there is 
a need to update the global evidence on RVGE age distribu-
tions, compare them between countries and regions, and es-
tablish a reliable method for extrapolating them to countries 
without data. An unpublished review was conducted in 2012 
[9], but this did not include the large multicountry Global 
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Rotavirus Surveillance Network (GRSN) database [10], and 
several pivotal multicountry studies have also been published 
since [11–13].
In this article, we aim to estimate granular age distributions 
of rotavirus disease outcomes in children aged <5 years by type 
of RVGE presentation, country, and mortality level, before the 
introduction of rotavirus vaccines. This article does not gen-
erate estimates of the potential impact of alternative rotavirus 
vaccination schedules but does provide inputs that will be im-
portant for those calculations.
METHODS
Ethical Approval
This study was approved by the ethical committee of the 
London School of Hygiene and Tropical Medicine (ethics refer-
ence number 14398). All authors and countries gave their con-
sent to analyze and publish the data.
Search Strategy and Study Selection
We sought country datasets containing counts of rotavirus-pos-
itive disease in children aged <5 years before the introduction 
of rotavirus vaccines. A country dataset is defined as a dataset 
derived from a single study (eg, hospital surveillance, case-con-
trol, cohort) within a single country, reporting on a single rota-
virus-positive outcome/presentation (community cases, clinic 
visits, emergency visits, hospitalizations, deaths). If a data-
set contained multiple subnational locations and/or multiple 
calendar years, then these were aggregated, and any relevant 
exclusion criteria were applied to the aggregated dataset. When 
studies reported multiple rotavirus-positive presentations, each 
presentation was considered to be a distinct dataset. Prevaccine 
datasets only included data for years prior to rotavirus vaccine 
introduction.
First, we analyzed the WHO GRSN database, which con-
tains information about hospital admissions among children 
aged <5  years from surveillance sites in 69 countries [10]. In 
these sites, rotavirus positivity is determined by enzyme immu-
noassay (EIA). We applied the definition described above and 
aggregated subnational locations and multiple calendar years to 
create unique prevaccine introduction GRSN country datasets. 
The year of rotavirus vaccine introduction was determined by 
WHO/United Nations Children’s Fund (UNICEF) estimates of 
national immunization coverage [14]. If a country dataset did 
not have data on hospital admissions by day of age, then we 
used month of age. Admissions recorded as aged zero days were 
removed for face validity (inconsistent with the rotavirus incu-
bation period).
Second, we conducted a systematic literature review adher-
ing to the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses  (PRISMA) guidelines to identify other 
relevant rotavirus studies. A  full description of the search 
strategy is provided in the Supplementary Appendix. In 
brief, we searched for papers published between January 
1990 and February 2017 and publications in English, French, 
Spanish, and Polish. We excluded studies in which rotavirus 
positivity was not determined by EIA or quantitative poly-
merase chain reaction; nonhuman studies; nosocomial infec-
tion studies; studies without information on individuals aged 
<5  years; special populations such as human immunodefi-
ciency virus–infected patients; meta-analyses and systematic 
reviews reporting regional or global age distributions; and 
papers without an accessible full-text link. Two independent 
reviewers (M. H.-A., C, N. L.) screened abstracts and any am-
biguity was resolved by a third reviewer (A. D. C.). A  letter 
was sent by email to the investigators of all studies identified 
in the systematic review. Investigators were asked to provide 
anonymized data or complete a standard data extraction table 
with counts by week of age up to 5.0 years. If the investigators 
did not respond before the end of August 2017 and no other 
study was available for that country, we extracted the age dis-
tribution reported in the publication. We included all country 
datasets that were obtained from a previously unpublished 
literature and database search conducted by Sanderson et al 
in 2012 [9]. This included articles published between 1990 
and 2011.
All country datasets were combined into a central database 
with a standard format and list of variables and analyzed to-
gether with the GRSN datasets. We cross-checked datasets 
identified through the literature search and GRSN to avoid 
data duplication. Prior to analyzing the datasets, we excluded 
studies that included <35 RVGE events, had known concerns 
about EIA quality, had <3 age bands <1  year of age, and did 
not capture cases from birth. We designed a tool to assess the 
risk of bias in randomized controlled trials and observational 
studies and assigned very low, low, or medium risk of bias to 
each country dataset. The risk of bias was scored against a list of 
5 criteria (Supplementary Appendix).
Data Analysis
We fit a range of parametric distributions (gamma, Weibull, 
log-normal, log-logistic, Burr) to several GRSN datasets that 
were reported by day of age, and that represented the extreme 
range of younger and older age distributions globally. We fit 
age distributions using maximum likelihood estimation. The 
best-fitting distribution was chosen by comparing goodness-
of-fit statistics (Kolmogorov-Smirnov, Cramer–von Mises, 
Anderson-Darling) and goodness-of-fit criteria (Akaike in-
formation criterion, Bayesian information criterion). For each 
country dataset, we calculated the best-fitting parameters of 
the chosen distribution. We generated summary tables with the 
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median age, interquartile age range, and the cumulative propor-
tion of RVGE cases aged <5 years that were estimated to occur 
at different granular ages between birth and age 5.0 years. We 
reported the root mean squared error and mean absolute error 
for the parametric distribution fitted to each country dataset. 
All analyses were conducted using R version 3.4.1 using the 
following packages: polspline, nloptr, zoo, MASS, fitdistrplus, 
actuar, and mutil.
We assigned each of the 201 countries in the world to an 
under-5 mortality quintile (very low, low, medium, high, 
and very high) using 2010–2015 estimates of under-5 mor-
tality as reported by the United Nations Population Division 
2017 revision [15]. We grouped all datasets according to the 
under-5 mortality quintile of the country concerned, and cal-
culated the median age and median best-fitting parameters 
for each stratum. We also ran a series of regression analyses 
to explore which combinations of variables would best pre-
dict the median age and parameters of the chosen parametric 
distribution. To compare differences in rotavirus disease pre-
sentations, we plotted the full set of median ages reported 
for a given presentation against their respective 2010–2015 
under-5 mortality rates. We fit a least-squares line of best fit 
for each presentation, reported the R2 value, and compared 
the best-fitting lines.
We used ArcGIS mapping software to display the median age 
of rotavirus hospitalization estimated for each country in the 
world. If more than a single dataset was available for a country, 
we calculated the median age and median best-fitting parame-
ters of all datasets for that country. If no dataset was available, 
we assigned the median age of the country’s corresponding 
mortality stratum.
RESULTS
We identified 117 prevaccination datasets with rotavirus-pos-
itive events among children <5  years of age (6 datasets with 
community cases, 12 with clinic visits, 7 with emergency vis-
its, 92 with hospital admissions, and 0 with deaths) (Table 1; 
Figure 1). Around half of the country datasets (51/117) were 
rotavirus-positive cases identified through hospital-based sen-
tinel site surveillance from the GRSN (35 reported by day of 
age and 16 reported by month of age). The other half (66/117) 
were identified from the systematic literature review (n = 61) 
or obtained from the previously unpublished review (n  =  5). 
The 117 prevaccination datasets were taken from 47 studies 
with very low (n = 24), low (n = 12), and medium (n = 11) risk 
of bias.
Log-logistic age distributions had favorable goodness-of-
fit statistics and criteria (Supplementary Figures 1 and 2), so 
were used to generate summary statistics on the age distri-
bution of hospital admissions aged <5 years (Supplementary 
Tables 2 and 3). The median age of RVGE hospital admis-
sion was 38 weeks (interquartile range [IQR], 25–58 weeks) 
in countries with very high child mortality, 43 weeks (IQR, 
28–68 weeks) in countries with high child mortality, 46 
weeks (IQR, 29–72 weeks) in countries with medium child 
mortality, and 65 weeks (IQR, 40–107 weeks) in countries 
with low/very low child mortality (Figure 2). We collapsed 
the low and very low child mortality strata because they had 
a similar median age (67 weeks for very low and 63 weeks 
for low) and regression analyses showed there was no differ-
ence between the 2 strata (P = .234; Supplementary Table 5, 
regression model 5). In countries with very high child mor-
tality, 69% of rotavirus-positive admissions in children aged 
<5 years were in the first year of life, with 3% by 10 weeks, 
8% by 15 weeks, and 27% by 26 weeks. There was consider-
able variation within each child mortality stratum. For ex-
ample, in the very high child mortality stratum, the median 
age ranged from 29 weeks (IQR, 19–46 weeks) in Zambia to 
50 weeks (IQR, 30–81 weeks) in Ethiopia. Similarly, in the 
low/very low mortality stratum, the median age ranged from 
35 weeks (IQR, 19–64 weeks) in France to 101 weeks (IQR, 
65–157 weeks) in Ukraine.
Globally, most countries with a low median age were in 
Africa (Figure 3). In general, the median age of rotavirus-posi-
tive hospital admissions decreased as child mortality increased 
Table 1. Number of Country Datasets Containing Rotavirus Gastroenteritis Age Distributions Before the Introduction of Rotavirus Vaccination, by Type of 
Presentation and Under-5 Mortality Quintile
Quintile for 2010–2015 Under-5 Mortality Rate
No. of Country Datasets (No. of Rotavirus-positive Cases)
Hospital Admissions Emergency Visits Clinic Visits Community Cases Total
Very low 13 (31 211) 3 (10 467) 3 (1552) 0 (0) 19 (43 230)
Low 8 (10 348) 2 (179) 1 (41) 0 (0) 11 (10 568)
Medium 14 (13 990) 0 (0) 1 (224) 1 (89) 16 (14 303)
High 31 (23 557) 2 (167) 3 (461) 4 (536) 40 (24 721)
Very high 26 (26 142) 0 (0) 4 (1066) 1 (71) 31 (27 279)
Total 92 (105 248) 7 (10 813) 12 (3344) 6 (696) 117 (120 101)
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Figure 1. Flowchart of the study selection process and data extraction. Some studies contained multiple datasets. Abbreviations: EIA, enzyme immunoassay; ELISA, 
enzyme-linked immunosorbent assay; GRSN, Global Rotavirus Surveillance Network; Pre-Vac, prevaccination; Post-Vac, postvaccination; RT-PCR, reverse-transcription poly-
merase chain reaction.
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(one-way analysis of variance; P  <  .0001), but there were no-
table outliers such as France and the Netherlands, where the 
median age was exceptionally low (35 and 48 weeks, respec-
tively), and Mauritius and Ukraine, where the median age was 
exceptionally high (84 and 101 weeks, respectively). Regression 
models with more variables provided no substantive advan-
tage over the simple stratification by under-5 mortality quintile 
(Supplementary Tables 4 and 5).
There were relatively few global datasets with age distribu-
tions for community cases, clinic visits, and emergency visits, 
and none for RVGE deaths that met our inclusion criteria. The 
median age for RVGE emergency visits was around 10 weeks 
younger than the median age for RVGE hospital admissions. 
The median age for RVGE clinic visits was around 5 weeks 
older than the median age for RVGE hospital admissions 
(Supplementary Tables 6–8). This pattern was consistent across 
settings with different under-5 mortality rates (Supplementary 
Figure 3).
DISCUSSION
We have gathered and synthesized a large amount of evidence 
on rotavirus age distributions globally. To our knowledge, 
this is the first systematic global study to estimate granular 
age distributions by country, mortality stratum, and level of 
care sought. We use statistically robust and standard methods 
to provide reproducible parametric age distributions for each 
country. We show that the median age of rotavirus disease 
varies between and within countries but tends to occur at a 
much younger age in higher-mortality settings. According to 
the basic principles of infectious disease dynamics, a younger 
average age of infection is likely to be associated with a 
higher force of infection. This is consistent with reported in-
cidence rates of rotavirus infection, which have been shown 
to peak at 5.5 months in Vellore, India (high mortality) and 
at 20 months in Mexico City (medium mortality). However, 
in these sites the overall rate of infection and the age distribu-
tion of symptomatic RVGE cases were not substantially dif-
ferent [16]. This is probably because infections among Indian 
children were less likely to protect against subsequent disease, 
leading to several cases in older Indian children [17, 18]. This 
is consistent with the lower protection acquired from doses 
of rotavirus vaccination in higher-mortality settings [19]. 
Our analysis of a much larger number of settings has shown 
that the most severe RVGE cases (ie, those being admitted to 
Figure 2. Age distributions of rotavirus-positive hospital admissions by under-5 mortality strata.
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Figure 3. Estimated and extrapolated prevaccination median age of rotavirus-positive hospital admissions in children aged <5 years, by country. Lighter red represents 
younger median age and darker red represents older median age. If >1 study was conducted within a country, the median of median ages was used. If no data were available 
for a country, the median age was extrapolated (indicated by diagonal shading) using the median age of the under-5 mortality stratum. Abbreviations: GRSN, Global Rotavirus 
Surveillance Network; RVGE, rotavirus gastroenteritis. The map is reprinted with permission from the World Health Organization.
hospital) tend to occur at younger ages in higher-mortality 
settings. We hypothesize that this is probably due to a higher 
force of infection and shorter intervals between repeat infec-
tions. There could also be important age-specific differences 
in the early management and treatment of RVGE in high-
er-mortality settings.
Our analysis relies heavily on the WHO GRSN database, 
which may include sentinel sites that are not fully representa-
tive of the country concerned. Importantly, healthcare-seek-
ing behavior varies by country and age, and this may help 
to explain heterogeneities observed within each mortality 
stratum. For example, in some settings with high rates of pri-
vate healthcare, children aged <1 year may be more likely to 
be treated outside of the regular sentinel surveillance system. 
In Hungary, Slovenia, and Ukraine, the median age of rotavi-
rus-positive hospital admissions was 86, 88, and 101 weeks, 
respectively. This high median age might simply be a char-
acteristic of rotavirus in Central and Eastern Europe or may 
reflect other surveillance peculiarities (eg, underrecruitment 
of younger patients or overrecruitment of mild RVGE cases). 
We analyzed the very low and low mortality strata without 
Ukraine, but that did not change the median age of 65 weeks. 
In other datasets, there may be a bias to younger ages. For 
example, we found a surprisingly low median age of hospital 
admission from multiple datasets in France (median age, 
27–41 weeks) for reasons that are not clear.
We chose to fit parametric distributions rather than report 
the actual age distributions observed in each study. This re-
quired an assumption to be made about the standard func-
tional form of the distribution. However, our parametric 
fitting approach (1) provides a function that can be easily 
reproduced by others; (2) avoids the issue of heaping—that 
is, the tendency to report cases at exactly 1.0 years, 2.0 years, 
etc, an issue that has been evident in many of the datasets be-
cause of a reporting artefact; (3) smooths distributions based 
on small (noisy) samples; and (4) allows standard reporting 
of the proportion of RVGE cases that occur at specific ages, 
for example, the proportion of cases occurring before the 
first dose of rotavirus vaccine at 6 weeks, or before vaccine 
age restrictions are applied at 15 weeks. We also explored 
nonparametric smoothing approaches. We used kernel den-
sity estimation, with default Gaussian smoothing. However, 
heaping was evident in some of the datasets, and areas of 
density below zero were common. One way to avoid this is to 
truncate the density at zero, but this introduces a bias in the 
distribution and creates an implausible cliff-edge at zero in 
some datasets. Another way to avoid this is to use logspline 
density estimation, with the lower bound set to zero. This 
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worked well for some datasets but not others and required 
manual adjustment to the number and location of knots, so 
it was not practical as a standardized approach.
We obtained many datasets on rotavirus-positive hos-
pital admissions but few on other presentations. No datasets 
with rotavirus-positive deaths met our inclusion criteria be-
cause they had <35 deaths, and it was very difficult to ascer-
tain whether the deaths were entirely attributable to rotavirus. 
Compared to hospital admissions, we found a higher median 
age for clinic visits and a younger median age for emergency 
visits, but this was based on very few data points and more data 
would be needed to confirm this.
In conclusion, the median age of rotavirus disease in children 
aged <5 years varies between and within countries but tends to 
be younger in higher-mortality settings. The age distributions 
presented in this article should provide information that is crit-
ical for assessing the potential benefits of alternative rotavirus 
vaccination schedules in different countries, and for monitor-
ing the impact of rotavirus vaccines.
Supplementary Data
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